DUBLIN--(
BUSINESS WIRE
)--The
"Acquired Gene or Chromosome Alterations Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2023 Update"
report has been added to
ResearchAndMarkets.com's
offering.
Acquired Gene or Chromosome Alterations Pipeline Report provides comprehensive information about the Acquired Gene or Chromosome Alterations pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
This report offers extensive coverage of Acquired Gene or Chromosome Alterations under development, providing comprehensive insights into pipeline products, major players, developmental activities, clinical trial data, and recent developments in the segment/industry.
Acquired Gene or Chromosome Alterations comprises of reagents employed for genetic testing to detect cancer causing/ related alterations, such as; k-ras, BRCA 1+2, Telomerase and HER-2/neu (human epidermal growth factor receptor 2).
The report reviews the details of major pipeline products, including product descriptions, licensing and collaboration details, and other developmental activities related to Acquired Gene or Chromosome Alterations. It also lists all the pipeline projects involving major players engaged in the development of Acquired Gene or Chromosome Alterations.
Coverage of pipeline products is based on various stages of development, ranging from Early Development to Approved/Issued stages, allowing readers to understand the progress of these products in the pipeline. Key clinical trial data related to ongoing trials specific to pipeline products in the Acquired Gene or Chromosome Alterations segment is provided, offering valuable insights into the clinical development of these products.
Reasons to Buy
Formulate significant competitor information, analysis, and insights to improve R&D strategies
Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
Identify and understand important and diverse types of Acquired Gene or Chromosome Alterations under development
Develop market-entry and market expansion strategies
Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
In-depth analysis of the product's current stage of development, territory and estimated launch date
Key Topics Covered:
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Acquired Gene or Chromosome Alterations Overview
3 Products under Development
3.1 Acquired Gene or Chromosome Alterations - Pipeline Products by Stage of Development
3.2 Acquired Gene or Chromosome Alterations - Pipeline Products by Territory
3.3 Acquired Gene or Chromosome Alterations - Pipeline Products by Regulatory Path
3.4 Acquired Gene or Chromosome Alterations - Pipeline Products by Estimated Approval Date
3.5 Acquired Gene or Chromosome Alterations - Ongoing Clinical Trials
4 Acquired Gene or Chromosome Alterations - Pipeline Products under Development by Companies
4.1 Acquired Gene or Chromosome Alterations Companies - Pipeline Products by Stage of Development
4.2 Acquired Gene or Chromosome Alterations - Pipeline Products by Stage of Development
5 Acquired Gene or Chromosome Alterations Companies and Product Overview
6 Acquired Gene or Chromosome Alterations- Recent Developments
7 Appendix
A selection of companies mentioned in this report includes
Abital Pharma Pipelines Ltd
Admera Health LLC
Agena Bioscience Inc
Aix-Marseille University
Albert Ludwigs University of Freiburg
Apteryx Imaging Inc
Baruch S. Blumberg Institute
Baylor College of Medicine
bioMerieux SA
Biotype Innovation GmbH
Blondin Bioscience, LLC
Cardiff Oncology Inc
Cepheid Inc
Children's Hospital Los Angeles
Children's Hospital of Philadelphia
China Medical Technologies Inc (Inactive)
Chronix Biomedical Inc
Columbia University
Duke University
Empire Genomics LLC
Fred Hutchinson Cancer Research Center
French National Institute of Health and Medical Research
Garvan Institute of Medical Research
Gencurix Inc
Genetag Technology, Inc
Genomic Health Inc
GenomicTree Co Ltd
German Cancer Research Center
H. Lee Moffitt Cancer Center & Research Institute Inc
Heali Ltd
Hebrew University of Jerusalem
Heidelberg Pharma AG
Helmholtz Centre for Infection Research
Inform Genomics Inc
Institute of Cancer Research
Interpace Biosciences Inc
iTP Biomedica Corp
Johns Hopkins University
Massachusetts General Hospital
Mayo Clinic
McGill University
MDNA Life Sciences Inc
MolecularMD Corp
Myriad International GmbH
Nel ASA
Northern California Institute for Research and Education
NucleoBio Inc
Ohio State University
OmicsWay Corp
Oxford Biodynamics Plc
Oxford Cancer Biomarkers Ltd
Pennsylvania State University
Princess Margaret Cancer Centre
QuantuMDx Group Ltd
Queen's University Belfast
Rosetta Genomics Ltd (Inactive)
Stanford University
Stony Brook University
Syamala Srinivasa Life Sciences Pvt. Ltd
Telo Genomics Corp
The Chinese University of Hong Kong
The University of New South Wales press Limited
The Walter and Eliza Hall Institute of Medical Research
TheraDiag SA
Therawis Diagnostics GmbH
Thrive Earlier Detection Corp
Total Brain Ltd
Trinity College Dublin
University College London
University of California San Diego
University of Cambridge
University of Central Florida
University of Cologne
University of Copenhagen
University of Hawaii at Manoa
University of Montreal
University of Rochester
University of South Carolina
University of Southern California
University of Strathclyde
University of Sydney
University of Texas Medical Branch at Galveston
University of Washington
Vyant Bio Inc
Wistar Institute
Yaathum Biotech Pvt Ltd
Yale University
For more information about this report visit
https://www.researchandmarkets.com/r/fb39kc
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.